Suppr超能文献

正常人类垂体和垂体腺瘤表达1型大麻素受体并合成内源性大麻素:大麻素在人类垂体水平对激素调节直接作用的首个证据。

Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level.

作者信息

Pagotto U, Marsicano G, Fezza F, Theodoropoulou M, Grübler Y, Stalla J, Arzberger T, Milone A, Losa M, Di Marzo V, Lutz B, Stalla G K

机构信息

Neuroendocrinology Group, Max Planck Institute of Psychiatry, 80804 Munich, Germany.

出版信息

J Clin Endocrinol Metab. 2001 Jun;86(6):2687-96. doi: 10.1210/jcem.86.6.7565.

Abstract

Little is known about the expression and function of cannabinoid receptor type 1 (CB1) in the human pituitary gland. The aim of this study was to investigate CB1 expression in human normal and tumoral pituitaries by in situ hybridization and immunohistochemistry using an antibody against CB1. CB1 was found in corticotrophs, mammotrophs, somatotrophs, and folliculostellate cells in the anterior lobe of normal pituitary. After examination of 42 pituitary adenomas, CB1 was detected in acromegaly-associated pituitary adenomas, Cushing's adenomas, and prolactinomas, whereas faint or no expression was found in nonfunctioning pituitary adenomas. Experiments with cultured pituitary adenoma cells showed that the CB1 agonist WIN 55,212--2 inhibited GH secretion in most of acromegaly-associated pituitary adenomas tested and that the CB1 antagonist SR 141716A was generally able to reverse this effect. Moreover, WIN 55,212--2 was able to suppress GHRH-stimulated GH release, and this effect was not blocked by coincubation with SR 141716A, possibly indicating a non-CB1-mediated effect. In contrast, WIN 55,212--2 was ineffective on GH-releasing peptide-stimulated GH release. In four Cushing's adenomas tested, WIN 55,212--2 was not able to modify basal ACTH secretion. However, simultaneous application of CRF and WIN 55,212--2 resulted in a synergistic effect on ACTH secretion, and this effect could be abolished by SR 141716A, demonstrating a CB1-mediated effect. In the single case of prolactinomas tested, WIN 55,212--2 was able to inhibit basal secretion of PRL. Finally, the presence of endocannabinoids (anandamide and 2-arachidonoylglycerol) was investigated in normal and tumoral pituitaries. All tumoral samples had higher contents of anandamide and 2-arachidonoylglycerol compared with the normal hypophysis. Moreover, endocannabinoid content in the different pituitary adenomas correlated with the presence of CB1, being elevated in the tumoral samples positive for CB1 and lower in the samples in which no or low levels of CB1 were found. The results of this study point to a direct role of cannabinoids in the regulation of human pituitary hormone secretion.

摘要

关于1型大麻素受体(CB1)在人垂体中的表达和功能,人们了解甚少。本研究的目的是通过原位杂交和使用抗CB1抗体的免疫组织化学方法,研究CB1在人正常垂体和肿瘤性垂体中的表达情况。在正常垂体前叶的促肾上腺皮质激素细胞、促乳腺激素细胞、促生长激素细胞和滤泡星状细胞中发现了CB1。在检查了42例垂体腺瘤后,在肢端肥大症相关垂体腺瘤、库欣腺瘤和催乳素瘤中检测到了CB1,而在无功能垂体腺瘤中发现微弱表达或无表达。对培养的垂体腺瘤细胞进行的实验表明,CB1激动剂WIN 55,212-2在大多数测试的肢端肥大症相关垂体腺瘤中抑制生长激素(GH)分泌,并且CB1拮抗剂SR 141716A通常能够逆转这种作用。此外,WIN 55,212-2能够抑制生长激素释放激素(GHRH)刺激的GH释放,并且这种作用不会因与SR 141716A共同孵育而被阻断,这可能表明存在非CB1介导的效应。相反,WIN 55,212-2对生长激素释放肽刺激的GH释放无效。在测试的4例库欣腺瘤中,WIN 55,212-2不能改变基础促肾上腺皮质激素(ACTH)分泌。然而,同时应用促肾上腺皮质激素释放因子(CRF)和WIN 55,212-2对ACTH分泌产生协同作用,并且这种作用可被SR 141716A消除,表明这是一种CB1介导的效应。在测试的唯一一例催乳素瘤中,WIN 55,212-2能够抑制催乳素(PRL)的基础分泌。最后,研究了正常垂体和肿瘤性垂体中内源性大麻素(花生四烯乙醇胺和2-花生四烯酸甘油酯)的存在情况。与正常垂体相比,所有肿瘤样本中花生四烯乙醇胺和2-花生四烯酸甘油酯的含量都更高。此外,不同垂体腺瘤中的内源性大麻素含量与CB1的存在相关,在CB1阳性的肿瘤样本中升高,而在未发现或低水平表达CB1的样本中较低。本研究结果表明大麻素在调节人垂体激素分泌中具有直接作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验